Which antidepressants have the lowest risk of serotonin syndrome?

Bupropion and mirtazapine have the lowest risk of serotonin syndrome among antidepressants

Bupropion is the safest choice for avoiding serotonin syndrome, as it lacks serotonergic activity and cannot precipitate serotonin toxicity even in overdose or when combined with MAO inhibitors. Mirtazapine is similarly safe, with evidence showing it is unable to precipitate serotonin toxicity in overdose or when mixed with MAO inhibitors 1.

Mechanism-Based Risk Stratification

Lowest Risk (Non-Serotonergic)

• Bupropion: No serotonergic mechanism; cannot cause serotonin syndrome alone or in combination 1
• Mirtazapine: Despite theoretical serotonergic effects in animal models, human data demonstrates inability to precipitate serotonin toxicity 1

Moderate Risk (Serotonergic but Lower Potency)

• Most tricyclic antidepressants (excluding clomipramine and imipramine): Do not precipitate serotonin toxicity and may not actually elevate serotonin in humans despite previous assumptions 1
• Moclobemide: Unable to precipitate serotonin toxicity in overdose 1

Higher Risk (Potent Serotonergic)

Among SSRIs, fluvoxamine carries the highest risk with a reporting odds ratio of 2.66 compared to other SSRIs 2. Sertraline and fluoxetine have the most absolute reports of serotonin syndrome, though this partly reflects their widespread use 2.

Critical Drug Interaction Considerations

The risk escalates dramatically with certain combinations:

• SSRIs + SNRIs: ROR 25.42 2
• SSRIs + tramadol or fentanyl: ROR 41.95 2
• MAO inhibitors: Highest class risk with ROR 45.99, followed by SSRIs at ROR 32.66 3

Important caveat: While linezolid theoretically poses risk, real-world data from 1,134 older patients showed serotonin syndrome occurred in fewer than 6 patients (<0.5%), with no significant increase when combined with antidepressants 4. This suggests theoretical concerns may exceed actual clinical risk for some combinations.

Clinical Decision Algorithm

For patients at high risk of serotonin syndrome (requiring opioids, multiple antidepressants, or with history of serotonin toxicity):

1. First choice: Bupropion
2. Second choice: Mirtazapine
3. Avoid: Fluvoxamine, MAO inhibitors, combinations of serotonergic agents

For patients requiring combination therapy:

• Avoid SSRI + SNRI combinations (ROR 25.42)
• If opioids needed, avoid tramadol and fentanyl with SSRIs
• Monitor closely but don't automatically avoid linezolid with antidepressants given low actual incidence 4

Risk Factors for Severe Outcomes

Higher reporting odds occur in:

• Males (higher ROR than females) 3
• Older adults (≥65 years) 3
• Patients on multiple serotonergic agents 2

The guidelines acknowledge that evidence on serotonin syndrome is scarce but emphasize it should be kept in mind when treating with second-generation antidepressants 5. However, the available pharmacovigilance data now provides clearer risk stratification than was available when these guidelines were published.